BCMA-Directed Agents for Multiple Myeloma
Nina Shah, MD, on BCMA-directed treatments for patients with multiple myeloma.
EP: 1.Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
EP: 2.Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
EP: 3.Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH
EP: 4.Biggest FDA News for Multiple Myeloma in 2021
EP: 5.Treatment Options for Transplant-Eligible Multiple Myeloma
EP: 6.Treatment Options for Transplant-Ineligible Multiple Myeloma
EP: 7.Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma
EP: 8.Understanding Adverse Events in Multiple Myeloma
EP: 9.BCMA-Directed Agents for Multiple Myeloma
EP: 10.Optimal Therapies for Relapsed/Refractory Multiple Myeloma
EP: 11.Emerging Research and Therapies for Multiple Myeloma
EP: 12.Upcoming Phase 3 Data in Multiple Myeloma
EP: 13.Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma
EP: 14.Looking Ahead to the Future of Multiple Myeloma Treatment
EP: 15.Current Leading Therapies for Multiple Myeloma
Nina Shah, MD: The BCMA [B-cell maturation antigen]–directed agents are generally FDA approved in later lines. For belantamab mafodotin [Blenrep], it’s after 4 treatments. For the CAR T-cell therapy [idecabtagene vicleucel], it’s after 4 lines. [Approvals contain] similar verbiage but [there are] subtle differences. We usually see these therapies being chosen in the late line. The issue is that not all BCMA[-directed] therapies are the correct match for all patients. For example, if you’re going to get a CAR T-cell therapy, it does require a lot of timing and coordination for which the patient has to be ready to come to a specialized center. For apheresis, [the patient] has to have a caregiver and has a plan that’s complicated, albeit a short plan because it’s a 2-month commitment to the specialized center. On the flip side, having a BCMA-directed antibody-drug conjugate is something that a patient can get off the shelf and can get in his or her community setting. It does require having an eyecare professional or eyecare specialist alongside to be able to manage and measure for keratopathy. These are all things you can do as an outpatient, and some people find that to be a very friendly regimen because they don’t have to go to a specialized center. The BCMA bispecifics will then be a hybrid because the first 1 or 2 doses may require being hospitalized or going to a specialized center that is used to dealing with CRS [cytokine release syndrome], or potentially neurotoxicity. Then after the first 1 or 2 doses, the patients will be able to get that therapy at home. Based on that, it will allow more patients to get that therapy and have it more available. Maybe they’re willing to pay in for the first week or 2 of therapy at a specialized center, but they won’t have to do that for long term. All of these therapies are very patient friendly after you get through the logistics, and I’ve been very impressed with how tolerable they are once you know how to manage the toxicities.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
